Market Data
Market Cap₹131.93 Cr.
52W High₹136.45
Current Price₹104.8
52W Low₹76.01
Down from 52W High23.2 %
Face Value₹10
Performance
ROCE11.93 %
ROE10.71 %
EPS (TTM)₹1.88
EPS Prev Qtr₹1.49
EPS Last Year₹1.71
EBITDA Qtr₹4.44 Cr.
Book Value₹51
Financial Health
Debt/Equity0.96
Debt/Profit9
Total Assets₹183.23 Cr.
Promoter Holding53.65 %
Earning Power7.32 %
Valuation
Stock P/E19.05
Industry P/E33.3
Price to Book2.04
Price to Sales0.77
Graham Number₹79.73
Key Metrics
Face Value
₹10
About Lactose (India) Ltd
Healthcare · Pharmaceuticals
Lactose (India) Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹10. Market cap ₹131.93 Cr.
Price Chart
Strengths & Weaknesses
Strengths
- The company has a ROCE of 14%, indicating efficient use of capital.
- The company has a ROE of 13.29%, showing strong returns generated on shareholders' equity.
- The company maintains a majority promoter holding at 53.65%, which may indicate better governance and alignment of interests.
Weaknesses
- The company has a relatively high P/E ratio of 18.27, suggesting it may be overvalued compared to peers.
- The P/B ratio of 2.42 indicates the market values the company at a premium over its book value.
- The company carries a debt to equity ratio of 1.08, indicating a significant level of leverage which could pose financial risk.
- Net profit of ₹6.94 Cr is relatively low compared to the revenue of ₹170.69 Cr, indicating thin profit margins.
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.9 | ₹4,46,276.3 Cr | 0.86% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 85.97 | ₹2,51,531.48 Cr | 0.32% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 78.4 | ₹1,86,956.51 Cr | 0.77% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 26.64 | ₹1,19,221.66 Cr | 0.08% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 33.13 | ₹1,11,725.01 Cr | 0.94% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 98.01 | ₹1,07,271.96 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Mankind Pharma Ltd | - | 51.42 | ₹1,05,107.48 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Dr Reddys Laboratories Ltd | - | 32.31 | ₹1,04,334.48 Cr | 0.64% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Aurobindo Pharma Ltd | - | 26.61 | ₹97,986.86 Cr | 0.23% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.63 | ₹94,189.9 Cr | 0.87% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 37.59 | ₹67,587.09 Cr | 0.1% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 29.02 | ₹62,609.02 Cr | 1.01% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 111.18 | ₹61,602.44 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.88 | ₹57,939.73 Cr | 1.74% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Gland Pharma Ltd | - | 43.62 | ₹49,299.85 Cr | 0.67% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Ipca Laboratories Ltd | - | 36.55 | ₹49,280.78 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 85 | ₹49,084.9 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 44.95 | ₹47,217.7 Cr | 2.05% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ajanta Pharma Ltd | - | 39.17 | ₹44,452.1 Cr | 0.79% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Sales | 41.18 | 36.77 | 45.77 | 46.97 |
| ↳ QoQ Growth | - | -10.7% | +24.5% | +2.6% |
| Expenses | 37.37 | 35.13 | 42.24 | 42.53 |
| Operating Profit | 3.81 | 1.64 | 3.52 | 4.44 |
| OPM % | 9.25% | 4.46% | 7.69% | 9.45% |
| Other Income | 0.37 | 0.63 | 0.22 | 0.56 |
| Interest | 1.04 | 1.39 | 1.43 | 1.76 |
| Depreciation | 1.44 | 1.43 | 1.5 | 1.64 |
| EBITDA | 5.25 | 3.07 | 5.02 | 6.08 |
| EBITDA Margin % | 12.75% | 8.35% | 10.97% | 12.94% |
| Profit Before Tax | 3.14 | 0.88 | 2.31 | 3.23 |
| Tax % | 31.53% | 39.77% | 18.61% | 26.93% |
| Net Profit | 2.16 | 0.53 | 1.88 | 2.37 |
| ↳ QoQ Growth | - | -75.5% | +254.7% | +26.1% |
| EPS | 1.71 | 0.42 | 1.49 | 1.88 |
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 12.589 | 12.59 |
| Reserves | 39.6256 | 52.2 |
| Borrowings | 56.19 | 62.45 |
| Other Liabilities | 25.06 | 55.99 |
| Total Liabilities | 133.4668 | 183.23 |
| Fixed Assets | 52.3237 | 69.02 |
| CWIP | 10.2394 | 0.27 |
| Investments | 0 | 0 |
| Other Assets | 70.9 | 113.94 |
| Total Assets | 133.4668 | 183.23 |
Cash Flows
| Mar 2025 | |
|---|---|
| Cash from Operating Activity | -0.2925 |
| Cash from Investing Activity | -15.5678 |
| Cash from Financing Activity | 18.8109 |
| Net Cash Flow | 2.9506 |
Shareholding Pattern
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Promoters % | 53.65% | 53.65% | 53.65% | 53.65% |
| FIIs % | 0% | 0% | 0% | 0% |
| DIIs % | 0.62% | 0.62% | 0.62% | 0.62% |
| Public % | 38.12% | 38.07% | 38.18% | 38.34% |
| No. of Shareholders | 16,810 | 16,770 | 16,670 | 16,554 |